false
0001712762
0001712762
2024-01-26
2024-01-26
0001712762
BIAF:CommonStockParValue.007PerShareMember
2024-01-26
2024-01-26
0001712762
BIAF:TradeableWarrantsToPurchaseCommonStockMember
2024-01-26
2024-01-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 26, 2024
BIOAFFINITY
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41463 |
|
46-5211056 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification Number) |
22211
W Interstate 10
Suite
1206
San
Antonio, Texas 78257
(210)
698-5334
(Address
of principal executive offices and Registrant’s telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $.007 per share |
|
BIAF |
|
The
Nasdaq Stock Market LLC |
Tradeable
Warrants to purchase Common Stock |
|
BIAFW |
|
The
Nasdaq Stock Market LLC |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
Management
Incentive Bonus Plan
On
January 26, 2024, the Compensation Committee of Bioaffinity Technologies, Inc. (the “Company”) adopted the Bioaffinity Technologies,
Inc. Management Incentive Bonus Plan (the “Plan”). The purpose of the Plan is to align officers’ and other employees’
efforts with the strategic goals of the Company through competitive annual incentive opportunities. The Plan will be administered by
the Compensation Committee of the Company’s Board of Directors. The Compensation Committee will have the power to grant awards
under the Plan, determine the amount of cash and/or equity to be paid pursuant to each award and the terms and conditions of each award.
Awards may provide for payment in installments, or upon the satisfaction of qualitative performance standards or quantitative performance
standards, on an individual, divisional or Company-wide basis, as determined by the Compensation Committee. Equity awards will be issued
in accordance with, and pursuant to, the Company’s Amended and Restated 2014 Equity Incentive Plan, as amended and/or any other
equity-related incentive plan maintained by the Company.
Each
participant in the Plan will be entitled to receive payment of the award for a Plan year only after certification by the Compensation
Committee that the targets associated with such award have been satisfied. Final payments with respect to awards will vary based on the
level of achievement measured against the pre-determined performance measures. Except as may be approved by the Compensation Committee,
each participant must be employed full-time on the date of payment, and not under a notice of termination, to receive the amount earned
under the award. Except as otherwise provided by the Compensation Committee, awards will be paid on or before March 15th following
the end of the Plan year in which payment under the award is earned. The Compensation Committee will have the discretion to reduce or
eliminate the amount otherwise payable to a participant if it determines that such a reduction or elimination is in the best interests
of the Company.
The
foregoing description of the Plan does not purport to be complete and is qualified in its entirety by reference to the Plan which is
attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Executive
Compensation
On
January 26, 2024, the Compensation Committee approved discretionary bonuses for each of Maria Zannes, Vivienne Rebel, Michael Dougherty,
Timothy Zannes, Xavier Reveles and Steven Girgenti for calendar year 2023 of $75,000, $100,000, $100,000, $21,000, $52,500 and
$37,500, respectively to be paid 50% in cash and 50% in shares of restricted stock. The bonuses shall be paid out on or before January
31, 2024. The number of shares of restricted stock to be issued shall be determined by dividing the cash value of 50% of each executive’s
bonus by the closing price of the Company’s common stock on January 31, 2024.
In
addition, the Compensation Committee approved an amendment (the “Amendment”) to Mr. Dougherty’s offer letter to amend
the terms of a restricted stock award previously granted to Mr. Dougherty pursuant to his offer letter (the “Prior Restricted Stock
Award”). The Amendment provides that upon a Change in Control (as defined in the Company’s Amended and Restated 2014 Equity
Incentive Plan, as amended), any outstanding and unvested portion of the Prior Restricted Stock Award shall vest in full immediately
prior to such Change in Control. The foregoing description of the Amendment does not purport to be complete and is qualified
in its entirety by reference to the Amendment which is attached hereto as Exhibit 10.2 and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
BIOAFFINITY
TECHNOLOGIES, INC. |
|
|
|
By: |
/s/ Maria
Zannes |
|
|
Maria Zannes |
|
|
President and Chief Executive
Officer |
Dated:
January 31, 2024
Exhibit
10.1
bioAffinity
Technologies, Inc.
MANAGEMENT
INCENTIVE BONUS PLAN
|
1. |
BACKGROUND
AND PURPOSE |
bioAffinity
Technologies, Inc., a Delaware corporation, hereby adopts the Management Incentive Bonus Plan (the “Plan”), effective as
provided in Paragraph 10. The purpose of the Plan is to align officers’ and other employees’ efforts with the strategic goals
of the Company through competitive annual incentive opportunities.
Under
the Plan, except where the context otherwise indicates, the following definitions apply:
(a)
“Affiliate” means, with respect to any Person, any other person that, directly or indirectly, is in control of, is
controlled by, or is under common control with, such Person. For purposes of this definition, the term “control,” including
its correlative terms “controlled by” and “under common control with,” mean, with respect to any Person, the
possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether
through the ownership of voting securities, by contract or otherwise.
(b)
“Award” means a cash and/or equity bonus award granted under the Plan. The equity awards will be issued in accordance
with, and pursuant to, the bioAffinity Technologies, Inc. Amended and Restated 2014 Equity Incentive Plan, as amended and/or any other
equity-related incentive plan maintained by the Company. Except as otherwise provided by the Committee, an Award shall be expressed as
the percentage of a Participant’s base salary payable for a Plan Year that shall become payable if the Targets established by the
Committee are satisfied. The portion of an Award that shall be payable to a Participant shall be determined by the Committee in accordance
with the rules established for the Award for each Plan Year.
(c)
“Board” means the Board of Directors of the Company.
(d)
“Change in Control” means:
(i)
Except as provided in Paragraph 2(d)(ii), “Change in Control” means (A) a change within a twelve-month period in the holders
of more than 50% of the outstanding voting stock of the Company; or (B) any other events deemed to constitute a “change in control”
by the Committee.
(ii)
With respect to the distribution of amounts subject to an Award that constitute “deferred compensation” (within the meaning
of Section 409A), the term “Change in Control” shall mean any transaction or series of transactions that constitutes a change
in the ownership or effective control or a change in the ownership of a substantial portion of the assets of the Company, within the
meaning of Section 409A.
(e)
“Committee” means the Compensation Committee of the Board, provided that all references to the Committee shall be
treated as references to the Committee’s delegate with respect to any Award granted within the scope of the delegate’s authority
pursuant to Paragraph 3(e).
(f)
“Company” means bioAffinity Technologies, Inc., a Delaware corporation, including any successor thereto by merger,
consolidation, acquisition of all or substantially all the assets thereof, or otherwise.
(g)
“Date of Grant” means the date on which an Award is granted.
(h)
“Disability” means:
(i)
A Participant’s substantial inability to perform the Participant’s employment duties due to partial or total disability or
incapacity resulting from a mental or physical illness, injury or other health-related cause for a period of twelve (12) consecutive
months or for a cumulative period of fifty-two (52) weeks in any twenty-four (24) consecutive-month period; or
(ii)
If more favorable to the Participant, “Disability” as it may be defined in such Participant’s employment agreement
between the Participant and the Company or an Affiliate, if any.
(i)
“Eligible Employee” means an employee of the Company or an Affiliate, as determined by the Committee.
(j)
“Participant” means an Eligible Employee who is granted an Award.
(k)
“Person” means an individual, a corporation, a partnership, an association, a trust or any other entity or organization.
(l)
“Plan” means this Management Incentive Bonus Plan as set forth herein, and as amended from time to time.
(m)
“Plan Year” means the Company’s fiscal year.
(n)
“Qualitative Performance Standards” means performance standards other than Quantitative Performance Standards, including
but not limited to customer service, management effectiveness, workforce diversity and other Qualitative Performance Standards relevant
to the Company’s business, as may be established by the Committee, and the achievement of which shall be determined in the discretion
of the Committee.
(o)
“Quantitative Performance Standards” means performance standards such as (a) income; (b) expense; (c) operating cash
flow; (d) capital spending; (e) total shareholder return, (f) gross margin; (g) growth in revenues, sales, market share, gross income,
net income, pre-tax income, stock price, and/or earnings per share, return on assets, net assets, and/or capital, working capital, free
cash flow and/or after tax cash flow, earnings before interest and taxes (EBIT), earnings before interest, taxes, depreciation, and amortization
(EBITDA); (h) EBITDA plus stock compensation; (i) return on shareholders’ equity, return on invested capital (j) economic or shareholder
value added, acquisition of assets, (k) acquisition of companies; (l) creation of new joint ventures; (m) growth in new products; (n)
lower product acquisition costs and/or improvements in costs and/or expenses, (o) stock price hurdles; (p) research and development of
product lines in the pipeline; (q) publications in peer-reviewed journals and presentations at scientific and medical conferences; and
(r) other objective financial or service-based standards relevant to the Company’s business as may be established by the Committee.
The performance standards may be measured relative to a peer group, an index or a business plan and may be considered as absolute measures
or changes in measures, relative to a pre-established target or to a previous year’s results, in each case as specified by the
Committee.
(p)
“Section 16(b) Officer” means an officer of the Company who is subject to the short-swing profit recapture rules of
Section 16(b) of the 1934 Act.
(q)
“Target” means, for any Plan Year, the Qualitative Performance Standards and the Quantitative Performance Standards
established by the Committee, in its discretion. Qualitative Performance Standards, Quantitative Performance Standards and the weighting
of such Standards may differ from Plan Year to Plan Year, and within a Plan Year, may differ among Participants or classes of Participants.
(r)
“Terminating Event” means any of the following events:
(i)
the liquidation of the Company; or
(ii)
a Change in Control.
|
3. |
ADMINISTRATION
OF THE PLAN |
(a)
Administration. The Plan shall be administered by the Committee. The Committee shall have the power and duty to do all things
necessary or convenient to effect the intent and purposes of the Plan and not inconsistent with any of the provisions hereof, whether
or not such powers and duties are specifically set forth herein, and, by way of amplification and not limitation of the foregoing, the
Committee shall have the power to:
(i)
provide rules and regulations for the management, operation and administration of the Plan, and, from time to time, to amend or supplement
such rules and regulations;
(ii)
construe the Plan, which construction, as long as made in good faith, shall be final and conclusive upon all parties hereto;
(iii)
correct any defect, supply any omission, or reconcile any inconsistency in the Plan in such manner and to such extent as it shall deem
expedient to carry the same into effect, and it shall be the sole and final judge of when such action shall be appropriate; and
(iv)
determine whether the conditions to the payment of a bonus pursuant to an Award have been satisfied.
The
resolution of any questions with respect to payments and entitlements pursuant to the provisions of the Plan shall be determined by the
Committee, and all such determinations shall be final and conclusive.
(b)
Grants. Subject to the express terms and conditions set forth in the Plan, the Committee shall have the power, from time to time,
to select those Eligible Employees to whom Awards shall be granted under the Plan, to determine the amount of cash and/or equity to be
paid pursuant to each Award, and, pursuant to the provisions of the Plan, to determine the terms and conditions of each Award.
(c)
Exculpation. No member of the Committee shall be personally liable for monetary damages for any action taken or any failure to
take any action in connection with the administration of the Plan or the granting of Awards thereunder unless (i) the member of the Committee
has breached or failed to perform the duties of the office, and (ii) the breach or failure to perform constitutes self-dealing, willful
misconduct or recklessness; provided, however, that the provisions of this Paragraph 3(c) shall not apply to the responsibility or liability
of a member of the Committee pursuant to any criminal statute.
(d)
Indemnification. Service on the Committee shall constitute service as a member of the Board. Each member of the Committee shall
be entitled without further act on the member’s part to indemnity from the Company to the fullest extent provided by applicable
law and the Company’s Certificate of Incorporation and Bylaws in connection with or arising out of any action, suit or proceeding
with respect to the administration of the Plan or the granting of Awards thereunder in which the person may be involved by reason of
the person’s being or having been a member of the Committee, whether or not the person continues to be such member of the Committee
at the time of the action, suit or proceeding.
(e)
Delegation of Authority. The Committee may delegate its authority with respect to the grant, amendment, interpretation and administration
of Awards, other than Awards to Section 16(b) Officers, to a person, persons or committee, in its sole and absolute discretion. Actions
taken by the Committee’s duly-authorized delegate shall have the same force and effect as actions taken by the Committee. Any delegation
of authority pursuant to this Paragraph 3(e) shall continue in effect until the earliest of:
(i)
such time as the Committee shall, in its sole and absolute discretion, revoke such delegation of authority;
(ii)
in the case of delegation to a person that is conditioned on such person’s continued service as an employee of the Company or as
a member of the Board, the date such delegate shall cease to serve in such capacity for any reason; or
(iii)
the delegate shall notify the Committee that he or she declines to continue to exercise such authority.
(f)
Participant Information. The Company shall furnish to the Committee in writing all Participant information the Company deems appropriate
for the Committee to exercise its powers and duties in administration of the Plan. Such information shall be conclusive for all purposes
of the Plan and the Committee shall be entitled to rely thereon without any investigation thereof; provided, however, that the Committee
may correct any errors discovered in any such information.
Awards
may be granted only to Eligible Employees of the Company and its Affiliates, as determined by the Committee. No Awards shall be granted
to an individual who is not an Eligible Employee of the Company or an Affiliate of the Company.
The
terms and conditions of Awards shall be as determined from time to time by the Committee, consistent, however, with the following:
(a)
Time of Grant. Awards may be granted at any time from the date of adoption of the Plan by the Committee until the Plan is terminated
by the Board or the Committee.
(b)
Non-uniformity of Awards. The provisions of Awards need not be the same with respect to each Participant.
(c)
Establishment of Targets and Conditions to Payment of Awards.
(i)
Except as otherwise provided by the Committee, Awards shall be expressed as a percentage of a Participant’s base salary.
(ii)
The Committee shall establish such conditions on the payment of a bonus pursuant to an Award as it may, in its sole discretion, deem
appropriate.
(iii)
The Award may provide for the payment of Awards in installments, or upon the satisfaction of Qualitative Performance Standards or Quantitative
Performance Standards, on an individual, divisional or Company-wide basis, as determined by the Committee.
(iv)
Each Participant shall be entitled to receive payment of the Award for a Plan Year only after certification by the Committee that the
Targets associated with the Award as established by the Committee for such Plan Year have been satisfied. Final payments with respect
to Awards will vary based on the level of achievement measured against the pre-determined performance measures.
(v)
Except as provided in Paragraph 5(e)(ii) or as may be approved by the Committee, each Participant must be employed full-time on the date
of payment to receive the amount earned under the Award. Except as otherwise provided by the Committee, Awards shall be paid on or before
March 15th following the end of the Plan Year in which payment under the Award is earned.
(vi)
For purposes of calculating whether any Quantitative Performance Standard has been met, the following effects may be eliminated: (i)
extraordinary, unusual, and/or nonrecurring items of gain or loss; (ii) gains or losses on the disposition of a business; (iii) dividends
declared on the Company’s stock; (iv) changes in tax or accounting principles, regulations or laws; (v) expenses incurred in connection
with a merger, acquisition or similar transaction; or (vi) such other effects that the Committee may approve to be eliminated.
(vii)
Notwithstanding the determination of the amount payable to a Participant under an Award with respect to any Plan Year under the Plan,
the Committee shall have the discretion to reduce or eliminate the amount otherwise payable to a Participant if it determines that such
a reduction or elimination of the amount payable is in the best interests of the Company.
(e)
Transfer and Termination of Participant’s Employment.
(i)
Transfer of Employment. A transfer of an Eligible Employee between two employers, each of which is the Company or an Affiliate
of the Company (a “Transfer”), shall not be deemed a termination of employment. The Committee may grant Awards pursuant to
which the Committee reserves the right to modify the calculation of an Award in connection with a Transfer. In general, except as otherwise
provided by the Committee at the time an Award is granted or in connection with a Transfer, upon the Transfer of a Participant between
Affiliates or divisions while an Award is outstanding and unexpired, the outstanding Award shall be treated as having terminated and
expired, and a new Award shall be treated as having been made, effective as of the effective date of the Transfer, for the portion of
the Award which had not expired or been paid, but subject to the performance and payment conditions applicable generally to Awards for
Participants who are employees of the transferee Affiliate or division, all as shall be determined by the Committee in an equitable manner.
(ii)
Termination of Employment. The Committee, in its sole and absolute discretion and to the extent permitted under and in accordance
with Section 409A, may, but is not required to, make a full or pro-rated payment to a Participant for a Plan Year in the event of the
Participant’s death, Disability, retirement, or termination of employment during the Plan Year or after the end of the Plan Year;
provided, that payments shall only be made on the earlier of (i) the death or Disability of the Participant or (ii) the payment date
established under Paragraph 5(c)(v).
(f)
Maximum Grant. In no event shall the amount paid to any Participant pursuant to an Award for any Plan Year exceed $2 million.
The
Committee shall give Participants at least thirty (30) days’ notice (or, if not practicable, such shorter notice as may be reasonably
practicable) prior to the anticipated date of the consummation of a Terminating Event. The Committee may, in its discretion, provide
in such notice that upon the consummation of such Terminating Event, any remaining conditions to payment of a Participant’s Award
shall be waived, in whole or in part.
|
7. |
AMENDMENT
AND TERMINATION |
The
Company reserves the right in its Board (or a duly authorized committee thereof) to amend, suspend or terminate the Plan or to adopt
a new plan in place of this Plan at any time. Furthermore, no amendment, suspension or termination shall, without the consent of the
Participant, alter or impair a Participant’s right to receive payment of the amount earned pursuant to an Award and payable hereunder
without the written consent of the Participant.
|
8. |
MISCELLANEOUS
PROVISIONS |
(a)
Unsecured Creditor Status. A Participant entitled to payment of an Award hereunder shall rely solely upon the unsecured promise
of the Company, as set forth herein, for the payment thereof, and nothing herein contained shall be construed to give to or vest in a
Participant or any other person now or at any time in the future, any right, title, interest, or claim in or to any specific asset, fund,
reserve, account, insurance or annuity policy or contract, or other property of any kind whatever owned by the Company, or in which the
Company may have any right, title, or interest, nor or at any time in the future.
(b)
Non-Assignment of Awards. No amount potentially payable under this Plan nor any right or benefit under this Plan shall be subject
to anticipation, alienation, sale, assignment, pledge, encumbrance, garnishment, execution or levy of any kind or charge before the date
on which payment is made, and any attempt to anticipate, alienate, sell, assign, pledge, encumber and to the extent permitted by applicable
law, charge, garnish, execute upon or levy upon the same shall be void and shall not be recognized or given effect by the Company. Except
as expressly provided by the Committee, the rights and benefits under the Plan shall not be transferable or assignable other than by
will or the laws of descent and distribution.
(c)
Other Company Plans. It is agreed and understood that any benefits under this Plan are in addition to any and all benefits to
which a Participant may otherwise be entitled under any other contract, arrangement, or voluntary pension, profit sharing or other compensation
plan of the Company, whether funded or unfunded, and that this Plan shall not affect or impair the rights or obligations of the Company
or a Participant under any other such contract, arrangement, or voluntary pension, profit sharing or other compensation plan.
(d)
Separability. If any term or condition of the Plan shall be invalid or unenforceable to any extent or in any application, then
the remainder of the Plan, with the exception of such invalid or unenforceable provision, shall not be affected thereby, and shall continue
in effect and application to its fullest extent.
(e)
Continued Employment. Neither the establishment of the Plan, any provisions of the Plan, nor any action of the Committee shall
be held or construed to confer upon any Participant the right to a continuation of employment by the Company. The Company reserves the
right to dismiss any employee (including a Participant), or otherwise deal with any employee (including a Participant) to the same extent
as though the Plan had not been adopted.
(f)
Incapacity. If the Committee determines that a Participant is unable to care for his affairs because of illness or accident, any
benefit due such Participant under the Plan may be paid to his spouse, child, parent, or any other person deemed by the Committee to
have incurred expense for such Participant (including a duly appointed guardian, committee, or other legal representative), and any such
payment shall be a complete discharge of the Company’s obligation hereunder.
(g)
Reporting and Withholding. The Company shall have the right to make such provisions as it deems necessary or appropriate to satisfy
any obligations it may have to withhold federal, state and/or local income or other taxes incurred by reason of payments pursuant to
the Plan or to report any amounts paid or payable under this Plan.
(h)
Application of Company Clawback Policy. All Awards under the Plan shall be subject to the provisions of any clawback or recoupment
policy approved by the Board and/or Committee, as such policy may be in effect from time to time.
The
Plan and all determinations made and actions taken pursuant to the Plan shall be governed in accordance with Delaware law.
The
Plan is effective for bonus awards granted on or after January 26, 2024.
Exhibit
10.2
AMENDMENT
TO OFFER LETTER
This
Amendment (this “Amendment”), effective as of the 26th day of January 2024, to the Offer Letter, dated
April 11, 2023 (the “Offer Letter”), by and between bioAffinity Technologies, Inc. (the “Company”)
and Michael Dougherty (“Dougherty”). Capitalized terms used herein without definition shall have the meanings assigned
in the Offer Letter.
WHEREAS,
the Company and Dougherty desire to amend the Offer Letter to provide that the equity award issued to Dougherty pursuant thereto will
vest in full upon a Change in Control (as defined in the Company’s 2014 Equity Incentive Plan, as amended).
NOW
THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend the Offer Letter as follows:
1.
Amendment. The following shall be inserted prior to the penultimate sentence in the fourth paragraph of the Offer Letter:
“Notwithstanding
anything herein to the contrary, the Equity Grant will vest (meaning the restrictions on the restricted stock will lapse) in full upon
and immediately prior to a Change in Control (as defined in the Company’s 2014 Equity Incentive Plan, as amended).”
2.
Severability. The provisions of this Amendment are severable and if any part of it is found to be unenforceable the other
paragraphs shall remain fully valid and enforceable.
3.
No Other Amendments; Confirmation. All other terms of the Agreement shall remain in full force and effect. The Agreement,
as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.
4.
Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but
both of which together shall constitute one and the same instrument.
5.
Governing Law. This Amendment is made and shall be construed and performed under the laws of the State of Texas without
regard to its choice or conflict of law principles and the parties agree to Texas as the exclusive venue for any disputes arising hereunder.
IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to the Offer Letter to be duly executed as of the day and year first
above written.
|
BIOAFFINITY
TECHNOLOGIES, INC. |
|
|
|
|
By:
|
/s/
Maria Zannes |
|
Name:
|
Maria
Zannes |
|
Title:
|
President
and Chief Executive Officer |
|
|
|
|
By: |
/s/
Michael Dougherty |
|
|
Michael
Dougherty |
v3.24.0.1
Cover
|
Jan. 26, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 26, 2024
|
Entity File Number |
001-41463
|
Entity Registrant Name |
BIOAFFINITY
TECHNOLOGIES, INC.
|
Entity Central Index Key |
0001712762
|
Entity Tax Identification Number |
46-5211056
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
22211
W Interstate 10
|
Entity Address, Address Line Two |
Suite
1206
|
Entity Address, City or Town |
San
Antonio
|
Entity Address, State or Province |
TX
|
Entity Address, Postal Zip Code |
78257
|
City Area Code |
210
|
Local Phone Number |
698-5334
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock Par Value. 007 Per Share [Member] |
|
Title of 12(b) Security |
Common
Stock, par value $.007 per share
|
Trading Symbol |
BIAF
|
Security Exchange Name |
NASDAQ
|
Tradeable Warrants To Purchase Common Stock [Member] |
|
Title of 12(b) Security |
Tradeable
Warrants to purchase Common Stock
|
Trading Symbol |
BIAFW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BIAF_CommonStockParValue.007PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BIAF_TradeableWarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jun 2024 to Jul 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jul 2023 to Jul 2024